This study is to evaluate the safety, tolerability, and pharmacokinetics of YR001 topical ointment in adult patients with mild to moderate atopic dermatitis
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Enrollment
35
The intervention is YR001 ointment on a range of body surface area for multiple topical administration
The intervention is Placebo on a range of body surface area for multiple topical administration
Encore Medical Research -Boynton Beach
Boynton Beach, Florida, United States
Encore Medical Research-Hollywood
Hollywood, Florida, United States
Encore Medical Research-Weston
Weston, Florida, United States
DelRicht Research
Baton Rouge, Louisiana, United States
The primary endpoint will be safety. Specifically, the primary endpoint will be the incidence of treatment-related AEs (TRAEs) through Day 50.
incidence of treatment related AEs (TRAEs)
Time frame: Day1-Day 50
all treatment-emergents AEs
number, severity, causality, and outcome of all treatment-emergetns AEs (TEAEs)
Time frame: Day1-Day 50
Efficacy of YR001 Ointment
Proportion of patients achieving ISGA 0 or 1 by visit
Time frame: Day1-Day50
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.